Indication

Vaccination to prevent anal cancer due to human papillomavirus

Anal cancer due to human papillomavirus (HPV) is a malignancy arising from the mucosal or squamous epithelium of the anal canal and perianal region, predominantly manifesting as squamous cell carcinoma. Read more about Vaccination to prevent anal cancer due to human papillomavirus

5 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Vaccination to prevent anal cancer due to human papillomavirus therapies.

Showing 1–5 of 5 drugs

Filter & compare in the drug finder →Opens the drug finder with Vaccination to prevent anal cancer due to human papillomavirus preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Vaccination to prevent anal cancer due to human papillomavirus.

Anal cancer due to human papillomavirus (HPV) is a malignancy arising from the mucosal or squamous epithelium of the anal canal and perianal region, predominantly manifesting as squamous cell carcinoma.

Pathophysiologically, persistent infection with high-risk oncogenic HPV subtypes—most notably HPV-16 and HPV-18—drives cellular transformation through viral oncoproteins that disrupt host tumor suppressor pathways, progressing through precancerous anal intraepithelial neoplasia (dysplasia).

While relatively rare in the general population, it disproportionately affects immunocompromised individuals, including people living with HIV, solid organ transplant recipients, and men who have sex with men.

Clinically, affected patients may remain asymptomatic or develop local symptoms such as rectal bleeding, anal pain, pruritus, tenesmus, or a palpable anal mass.

Personalize your experience

Follow Vaccination to prevent anal cancer due to human papillomavirus and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it